Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans
Anjaneya Chimalakonda, Bindu Murthy(Bristol-Myers Squibb (United States)), Prashant P. Deshpande(Bristol-Myers Squibb (Germany)), David Marchisin(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Wenying Li(Huanggang Normal University), Bing He(Xinqiao Hospital), Urvi Aras(Bristol-Myers Squibb (Germany)), Jonathan Brown(Tulane University)
Cited by 2
Related Papers
Nature and significance of endoleaks and endotension: Summary of opinions expressed at an international conference
|Journal of Vascular Surgery|2002|616
Construction of the third-generation <i>Zea mays</i> haplotype map
|GigaScience|2017|416
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
The genomic origins of the Bronze Age Tarim Basin mummies
|Nature|2021|191